Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1990-07-05
1992-04-14
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 424 858, 4352402, 43524021, 43524025, A61K 3702, A61K 3900, C12N 502
Patent
active
051046520
ABSTRACT:
Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G.sub.D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G.sub.D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab').sub.2 fragments) reacting with G.sub.D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G.sub.D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.
REFERENCES:
patent: 4507391 (1985-03-01), Pukel et al.
patent: 4844893 (1989-07-01), Honsuk et al.
Kasugi et al., Jpn, I Cancer Chemother. 11(8) 1984, pp. 1527-1537 (English translation).
Hersey et al., Cancer Res., 12/86, vol. 46, pp. 6083-6090.
Honsik et al., PNAS, 10/86, pp. 7893-7897, vol. 83.
Hersey et al., Australian & New Zealand J. of Medicine (Feb. 1986) vol. 16:152.
Chapman Paul
Houghton Alan N.
Miller Glenn
Old Lloyd J.
Welte Karl
Draper Garnette D.
Konski Antoinette
Sloan-Kettering Institute for Cancer Research
White John P.
LandOfFree
Compositions and method for treatment of cancer using monoclonal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and method for treatment of cancer using monoclonal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and method for treatment of cancer using monoclonal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2347660